© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
GSK plc (GSK) stock surged +1.79%, trading at $60.23 on NYSE, up from the previous close of $59.17. The stock opened at $59.29, fluctuating between $59.25 and $60.37 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Feb 06, 2026 | 59.29 | 60.37 | 59.25 | 60.23 | 8.15M |
| Feb 05, 2026 | 57.79 | 59.62 | 57.73 | 59.17 | 13.08M |
| Feb 04, 2026 | 56.56 | 57.62 | 56.33 | 57.23 | 10.88M |
| Feb 03, 2026 | 52.49 | 53.38 | 52.43 | 53.34 | 6.2M |
| Feb 02, 2026 | 52.17 | 52.67 | 52.13 | 52.47 | 4.15M |
| Jan 30, 2026 | 51.14 | 51.69 | 51.06 | 51.60 | 5.49M |
| Jan 29, 2026 | 50.82 | 51.09 | 50.63 | 50.66 | 5.9M |
| Jan 28, 2026 | 50.17 | 50.61 | 49.60 | 50.10 | 5.88M |
| Jan 27, 2026 | 50.49 | 51.37 | 50.49 | 50.80 | 5.1M |
| Jan 26, 2026 | 49.77 | 50.57 | 49.74 | 50.32 | 4.22M |
| Jan 23, 2026 | 48.74 | 49.16 | 48.57 | 49.15 | 5.43M |
| Jan 22, 2026 | 48.41 | 48.75 | 48.08 | 48.65 | 4.56M |
| Jan 21, 2026 | 47.85 | 48.38 | 47.77 | 48.07 | 6.51M |
| Jan 20, 2026 | 48.05 | 48.35 | 47.62 | 47.65 | 8.2M |
| Jan 16, 2026 | 48.85 | 48.93 | 48.09 | 48.22 | 7.5M |
| Jan 15, 2026 | 50.48 | 50.50 | 49.07 | 49.12 | 6.54M |
| Jan 14, 2026 | 50.20 | 50.87 | 50.16 | 50.79 | 3.68M |
| Jan 13, 2026 | 49.93 | 50.07 | 49.32 | 49.90 | 3.69M |
| Jan 12, 2026 | 50.80 | 50.82 | 50.17 | 50.39 | 2.64M |
| Jan 09, 2026 | 50.43 | 50.81 | 50.36 | 50.39 | 3.93M |
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; two strategic collaborations with Relation to advance therapeutics for fibrotic diseases and osteoarthritis; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.
| Employees | 68629 |
| Beta | 0.25 |
| Sales or Revenue | $30.33B |
| 5Y Sales Change% | -0.045% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |